Table 1.

Latest international recommendations for two-drug regimens in cART-naïve patients.

Regimen	DHHS 2021 [2]	IAS-USA 2020 [3]	EACS 2020 [4]
DTG+3TC	Recommended [AI] a VL < 500,000 HBsAg negative	Recommended [AIa] d VL < 500,000 CD4 > 200 (perhaps) HBsAg negative	Recommended VL < 500,000 HBsAg negative
DRV/r or DRV/c + RAL	Alternative [CI] b VL < 100,000 CD4 > 200		Alternative b HBsAg negative VL < 100,000 copies/mL CD4 > 200 cells/μL With food
DRV/r or DRV/c + 3TC	Alternative [CI] b,c

^a Except for individuals with HIV RNA > 500,000 copies/mL, HBV co-infection, or in whom cART is to be started before the results of HIV genotypic resistance testing for reverse transcriptase or HBV testing are available. ^b When the use of tenofovir disoproxil, tenofovir alafenamide, or abacavir is contraindicated or not desirable; ^c 3TC may be substituted for entricitabine, or vice versa; ^d Except for individuals with HIV RNA >500,000 copies/mL, HBV co-infection, currently treated for an active opportunistic infection, or in whom cART is to be started before the results of baseline laboratory evaluation. Exclusion of patients with CD4 cell count below 200/μL is unclear. 3TC = lamivudine; DRV/r = darunavir/ritonavir; DTG = dolutegravir; EACS = European AIDS Clinical Society; DHHS = U.S. Department of Health and Human Services; IAS = International AIDS Society; LPV/r = lopinavir/ritonavir; RAL = raltegravir; VL = viral load.